SCHEMBL23580608

SCHEMBL23580608

CN(C(=O)c1ncc(N=C(c2ccccc2)c2ccccc2)cc1C(F)F)C1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 1/20 0.36
▸ KDM5A P29375 1/20 0.36
▸ DPP4 P27487 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ PDE4B Q07343 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ CCR5 P51681 3/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ MASP2 O00187 1/20 0.33
▸ CTSG P08311 1/20 0.33
▸ PDGFRB P09619 1/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ PDGFRA P16234 1/20 0.32
▸ FLT1 P17948 1/20 0.32
▸ FGFR3 P22607 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29882638 1.00 CCR3 (0.36) CCR3KDM5ADPP4DPP9DPP7
SCHEMBL23608666 0.87 KMT2A (0.34) RAB9APDGFRBKDR
SCHEMBL23608500 0.83 KMT2A (0.34) PDK2PDGFRBKDR
SCHEMBL23580504 0.79 NPC1 (0.39) NPC1RAB9A
SCHEMBL29882674 0.79 NPC1 (0.39) NPC1RAB9A
SCHEMBL29882323 0.75 L3MBTL3 (0.39) DPP4PDK2POLB
SCHEMBL23580331 0.75 L3MBTL3 (0.39) DPP4PDK2POLB
SCHEMBL23580108 0.75 DPP4 (0.35) DPP4DPP9DPP7BTKPDE4B
SCHEMBL23580611 0.75 DPP4 (0.35) DPP4DPP9DPP7PDE4BPOLB
SCHEMBL24364780 0.73 ESR2 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2025-05-01 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 — — WO disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 — — WO disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 — — CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS MALT1, SQSTM1, FKBP1A CCR3 4650/4885KDM5A 1445/4885DPP4 1334/4885
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A CCR3 1393/4885KDM5A 3546/4885DPP4 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback